Reports as of December 31PMV Pharma had $228.6M in cash, cash equivalents, and marketable securities, compared to $243.5M at December 31, 2022. Net cash used in operations was $55.7 million for the year ended December 31 compared to $63.8M for the year ended December 31, 2022. Net loss for the year ended December 31 , was $69M compared to $73.3M for the year ended December 31, 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PMVP:
- PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
- PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
- PMV Pharmaceuticals annouces strategic 30% workforce reduction
- PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
- PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
